The biotechnology company Amfora has entered into a non-exclusive research and commercial license agreement with Corteva Agriscience and the Broad Institute of MIT and Harvard. Through the terms of this agreement, Amfora will use intellectual property covering CRISPR-Cas9 and related gene editing tools to develop gene-edited crops with a higher protein content.